Trial reportJournal of oral rehabilitation2025
Effect on Pain Following One Session of Botulinum Toxin Type A in Patients With Jaw Myalgia: A Randomised Double-Blind Controlled Multicentre Pilot Study.
Trial report in Journal of oral rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Two Botulinum Toxin A Injections in Patients With Chronic Orofacial Myalgia: A Randomised, Double-Blind, Controlled Multicenter Trial With Nine-Month Follow-Up.Journal of oral rehabilitation · 2025Trial
- One Molecule, Different Circuits? What Botulinum Toxin Can and Cannot Reveal About Craniocervical Comorbidity.Toxins · 2026Review
- Effect of occlusal splint design and thickness on temporomandibular joint loading: a finite element study.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBotulinum toxin Type A (BTX-A) is increasingly used in the management of myofascial pain; however, the evidence to support this treatment modality is still inconclusive.
objectiveTo evaluate the change in days with functional jaw pain after one session of BTX-A or placebo injections into the masseter and temporalis muscles in subjects with jaw myalgia. The hypothesis was that BTX-A is effective in reducing the number of days with functional jaw pain.
methodsThis was a randomised, double-blind, parallel group study in subjects with jaw myalgia. After randomisation, BTX-A or placebo injections were made in the masseter and temporalis muscles. The number of days with jaw pain on function was evaluated after 2 months. Adverse events were registered.
resultsTwenty-three subjects were randomly assigned to BTX-A and 22 to placebo. Between baseline and the 2-month follow-up, the number of days with jaw pain at function changed from a median (interquartile range) of 14 (4) to 10.5 (6) days in the BTX-A group and from 14.0 (1.5) to 14 (5) in the saline group (p < 0.585). Adverse events were mild and transient and similar in the two groups.
conclusionA single treatment of BTX-A injections in the masseter and temporalis muscles was not effective in treating jaw myalgia. However, an adequately powered study might provide sufficient support for efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.